Grufity logoGrufity logo

TXG

36.19USD+0.35(+0.98%)Delayedas of 28 Nov 2022, 10:08 am

10x Genomics, Inc.

Market Summary

USD36.19+0.35Delayedas of 28 Nov 2022, 10:08 am
0.98%

TXG Stock Price

RSI Chart

Valuation

Market Cap

3.1B

Price/Earnings

-21.82

Price/Sales

6.25

Price/Cashflow

-53.45

MarketCap/EBT

-22.51

Price/Sales

Profitability

Operating Margin

78.85%

EBT Margin

-27.75%

Return on Equity

-18.19%

Return on Assets

-14.23%

Fundamentals

Revenue

Revenue (TTM)

497.9M

Revenue Y/Y

-1.06%

Revenue Q/Q

0.1%

Earnings

Earnings (TTM)

-142.5M

Earnings Y/Y

-483.22%

Earnings Q/Q

-51.98%

Price Action

52 Week Range

23.81157.74
(Low)(High)

Last 7 days

1.5%

Last 30 days

28.9%

Last 90 days

2.7%

Trailing 12 Months

-76.3%

Financial Health

Current Ratio

5.65

Investor Care

Shares Dilution (1Y)

3.38%

Diluted EPS (TTM)

-1.27

Peers (Alternatives to 10x Genomics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
14.00% 3.09%
30.93
6.17
8.42% 34.14%
36.7B
4.7B
-7.73% -40.09%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
14.80% -4.52%
34.68
7.36
7.75% 11.02%
18.1B
2.9B
12.03% -1.70%
25.81
6.25
8.61% 6.30%
17.2B
4.6B
0.36% -22.59%
25.45
3.42
-9.73% -44.26%
MID-CAP
SMALL-CAP
2.0B
137.0M
14.63% -56.78%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
8.70% -71.21%
-4.68
6.81
19.67% -35.56%
661.5M
23.3M
-12.60% -45.72%
-6.25
28.36
76.56% -106.44%
488.2M
135.3M
-43.15% -85.19%
-3.51
3.42
-2.59% -32.75%
413.2M
110.0M
8.29% -73.27%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-6.72% -85.20%
-19.64
2.76
31.03% -107.73%
122.6M
69.0M
-6.93% -82.43%
-1.31
1.6
-18.80% -75.52%
109.5M
118.0M
- -66.15%
-29.97
0.91
0.97% -269.58%
95.7M
51.6M
-4.83% -20.62%
238.75
1.86
20.72% 150.31%

Financials for 10x Genomics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue-0.2%498499490459406
Gross Profit-5.8%393417416394350
Operating Expenses5.7%529500469840846
  S&GA Expenses4.0%278267258244233
Earnings Before Taxes-63.9%-138.17-84.29-53.71-446.34-494.96
Net Income-59.9%-142.49-89.08-58.22-455.35-504.02
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-0.2%1,0021,0031,019991978
  Current Assets-4.5%666697748744757
    Cash Equivalents-12.0%282320587609649
  Inventory10.9%7164605144
  Net PPE17.2%223190169143122
  Goodwill0%55555
Liabilities10.9%218197201190193
  Current Liabilities24.8%11894110100113
Shareholder's Equity-2.9%784807818800785
  Retained Earnings-7.1%-970.19-905.73-863.32-844.87-827.70
  Additional Paid-In Capital2.5%1,7581,7151,6811,6451,612
Accumulated Depreciation10.4%494439--
Shares Outstanding0.5%114113113111110
Float-18,700----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-52.7%-58.18-38.09-21.37-157.35-186.77
  Share Based Compensation8.9%115106968371
Cashflow From Investing-4.1%-332.93-319.97-106.73-101.38-82.46
Cashflow From Financing-28.8%24343534514

Risks

What is the probability of a big loss on TXG?

85.2%


Probability that 10x Genomics stock will be more than 20% underwater in next one year

60.4%


Probability that 10x Genomics stock will be more than 30% underwater in next one year.

53.9%


Probability that 10x Genomics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TXG drawdown profile look like?

Y-axis is the maximum loss one would have experienced if 10x Genomics was unfortunately bought at previous high price.

Returns

Cumulative Returns on TXG

-17.6%


3-Year Cumulative Returns

Which funds bought or sold TXG recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,992,000
1,992,000
0.02%
2022-11-22
Capital Impact Advisors, LLC
NEW
-
82,000
82,000
0.08%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-1,894,000
3,113,000
-%
2022-11-16
GLENMEDE TRUST CO NA
SOLD OFF
-100
-303,000
-
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-10,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
-155,000
264,000
-%
2022-11-15
State of Tennessee, Treasury Department
UNCHANGED
-
-
1,148,000
-%
2022-11-15
Balyasny Asset Management LLC
SOLD OFF
-100
-1,364,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
ADDED
2
-734,000
1,315,000
0.01%

1–10 of 46

Latest Funds Activity

Are funds buying TXG calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TXG

10x Genomics News

MarketBeat

10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $55397.82 in Stock.4 days ago

TXG Fair Value

Recent SEC filings of 10x Genomics

View All Filings
Date Filed Form Type Document
Nov 23, 2022
4
Insider Trading
Nov 23, 2022
4
Insider Trading
Nov 23, 2022
4
Insider Trading
Nov 03, 2022
10-Q
Quarterly Report
Nov 02, 2022
8-K
Current Report
Sep 16, 2022
4
Insider Trading
Sep 16, 2022
4
Insider Trading
Sep 16, 2022
4
Insider Trading
Sep 16, 2022
4
Insider Trading
Sep 16, 2022
4
Insider Trading

Latest Insider Trading transactions for TXG

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-22
Saxonov Serge
SOLD
-91,158.4
34.0652
-2,676
Chief Executive Officer
2022-11-22
McAnear Justin J.
SOLD
-55,392.1
34.0665
-1,626
Chief Financial Officer
2022-11-22
Hindson Benjamin J.
SOLD
-80,433.6
34.0676
-2,361
See Remarks
2022-09-14
McAnear Justin J.
ACQUIRED
-
-
20,297
Chief Financial Officer
2022-09-14
Wilbur James
ACQUIRED
-
-
95,839
Chief Commercial Officer
2022-09-14
Hindson Benjamin J.
ACQUIRED
-
-
33,828
See Remarks
2022-09-14
Kosaraju Sridhar
ACQUIRED
114,800
11.48
10,000
-
2022-09-12
Saxonov Serge
ACQUIRED
13,800
1.2
11,500
Chief Executive Officer
2022-08-23
Saxonov Serge
SOLD
-95,544.4
35.1913
-2,715
Chief Executive Officer
2022-08-23
Hindson Benjamin J.
SOLD
-45,467.2
35.1913
-1,292
See Remarks

1–10 of 50

Serge Saxonov
1240
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 131,072$ 125,297$ 360,177$ 346,960
Cost of revenue30,37724,51883,55946,493
Gross profit100,695100,779276,618300,467
Operating expenses:    
Research and development67,29054,582202,053149,867
Selling, general and administrative73,40162,076219,413187,683
Accrued contingent liabilities000(660)
Total operating expenses140,691116,658421,466336,890
Loss from operations(39,996)(15,879)(144,848)(36,423)
Other income (expense):    
Interest income2,025493,832157
Interest expense(114)(219)(351)(649)
Other expense, net(1,950)(599)(4,193)(807)
Total other expense(39)(769)(712)(1,299)
Loss before provision for income taxes(40,035)(16,648)(145,560)(37,722)
Provision for income taxes1,8795233,2252,052
Net loss$ (41,914)$ (17,171)$ (148,785)$ (39,774)
Net loss per share, basic (in dollars per share)$ (0.37)$ (0.15)$ (1.31)$ (0.36)
Net loss per share, diluted (in dollars per share)$ (0.37)$ (0.15)$ (1.31)$ (0.36)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)114,112,382110,874,249113,555,750109,826,104
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)114,112,382110,874,249113,555,750109,826,104

TXG Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 233,951$ 587,447
Marketable securities218,4350
Restricted cash5081,028
Accounts receivable, net83,54985,254
Inventory78,62959,966
Prepaid expenses and other current assets14,35013,896
Total current assets629,422747,591
Property and equipment, net257,694169,492
Restricted cash7,0917,598
Operating lease right-of-use assets71,09560,918
Goodwill4,5114,511
Intangible assets, net23,49325,397
Other noncurrent assets2,9013,319
Total assets996,2071,018,826
Current liabilities:  
Accounts payable21,59417,351
Accrued compensation and related benefits28,21431,626
Accrued expenses and other current liabilities61,98950,909
Deferred revenue6,6655,340
Operating lease liabilities8,3935,131
Total current liabilities126,855110,357
Accrued license fee, noncurrent05,814
Operating lease liabilities, noncurrent87,83376,847
Other noncurrent liabilities5,7278,240
Total liabilities220,415201,258
Commitments and contingencies (Note 5)
Stockholders’ equity:  
Preferred stock00
Common stock22
Additional paid-in capital1,793,3881,680,865
Accumulated deficit(1,012,106)(863,321)
Accumulated other comprehensive income (loss)(5,492)22
Total stockholders’ equity775,792817,568
Total liabilities and stockholders’ equity$ 996,207$ 1,018,826